Navigation Links
Takeda submits new drug application for alogliptin (syr-322) in the US
Date:1/4/2008

Deerfield, IL, January 3, 2008 --- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes. Discovered by Takeda San Diego, Inc., alogliptin was designed to selectively inhibit DPP-4 taken orally once daily.

DPP-4 inhibitors are a new class of oral agents for the treatment of type 2 diabetes, which slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). The incretins play a major role in regulating blood glucose levels and may have the potential to improve pancreatic beta-cell function.

The NDA submission was supported by six Phase 3 clinical trials involving over 2,000 patients conducted in 220 centers worldwide. The safety and efficacy of alogliptin was studied as a once-daily monotherapy adjunct to diet and exercise and as an add-on therapy to other antidiabetic medications including sulfonylureas, metformin, thiazolidinediones (TZDs), and insulin. In the studies, alogliptin was associated with statistically significant reductions in hemoglobin A1c, which reflects average blood glucose concentration over the previous two to three months. Alogliptin was generally well-tolerated and weight neutral. There was no increase in hypoglycemia compared to placebo.

The NDA submission for alogliptin is a significant milestone for Takeda, as it has the potential to position us as one of the global leaders in diabetes treatment, said Yasuchika Hasegawa, president of Takeda. Takedas continued growth, now and in the future, will be based on our ability to focus and have success in this therapeutic area. Our hope is that alogliptin will become an important t
'/>"/>

Contact: Carrie Rose
carrie.rose@ketchum.com
646-935-3938
Takeda Pharmaceuticals North America
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Chemizon Announces Research Collaboration Expansion With Takeda
2. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
3. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
4. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
5. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
6. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
7. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
8. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
9. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
10. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 01, 2015 Carson Energy also ... their investors IRA transactions. AdvantaIRA Trust, LLC is the ... the ability to fund positions using IRA’s does 2 ... on a project, even if there current cash position ... additional funding source for Carson and their investors to ...
(Date:6/1/2015)... June 01, 2015 Ticket Down announces that ... NBA Western Conference Finals and now will face the Cleveland ... be held at the Oracle Arena in Oakland and the ... 2014-15 National Basketball Association season, the Golden State Warriors were ... a team that learned from their playoff failures from the ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 The federal ... has amended the Case Management Order governing case ... gel. The Amended Order which was issued in ... May 29, 2015, directs the parties to submit a ... 10, 2015 that outlines parameters and the process for ...
(Date:6/1/2015)... Unlike most generator rental companies, which raise their rates ... to when the generator is in standby mode, WPP charges ... generator or not. WPP also offers an offsite storage option ... a few hours — for companies that do not have ... , “Even minor business disruptions are very expensive for commercial ...
(Date:6/1/2015)... Atagi Plastic Surgery and Skin Aesthetics is ... Ultherapy® Ultra Treatment Provider by Ulthera, the manufacturer ... one of only six practices in Colorado to be ... , Atagi Plastic Surgery and Skin Aesthetics’ experience and ... the practice to earn the distinction of being named ...
Breaking Medicine News(10 mins):Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 4Health News:Worldwide Power Products Offers “Budget Billing” Contingency Generator Rental Program; Guarantees Power for Peak of Hurricane Season and Beyond 2Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2
... 2008 Diplomat Specialty,Pharmacy today announced Mike ... of,National Accounts. Maynard reports directly to Dr. ... Maynard is responsible for the development and ... initially on chronic,kidney disease, dialysis, and renal ...
... NEW YORK, April 8, 2008 Lierac Paris, Europe,s,celebrated ... in select Healthy Skincare Centers at CVS/pharmacy throughout the,Northeast., ... Current store openings are as follows: ... by April 30, 2008 Northeast U.S. (NY ...
... microwave therapy for enlarged prostates experience significant surges in ... heart attack or stroke, according to new research findings ... Clinic-led study of 185 consecutive patients who received transurethral ... percent experienced systolic blood pressure surges of more than ...
... In short-term health care settings, sophisticated information technology ... care management, and enhance adherence to clinical guidelines. However, ... are unknown. In response to recent efforts from policy ... University of Missouri researcher found, through two different studies, ...
... by Attendees, BLACKWOOD, N.J., April 8, ... Healthcare Educational Forum in conjunction with,Wake Forest ... took,place in Winston-Salem, North Carolina on March ... integrated delivery networks and healthcare,information systems across ...
... April 8, 2008 ,GlaxoSmithKline (NYSE: GSK ) ... the US Food and Drug Administration (FDA) related ... a routine FDA,inspection of GSK,s reporting processes conducted ... primarily relate to omissions from,periodic reports to the ...
Cached Medicine News:Health News:Diplomat Specialty Pharmacy Hires National Accounts Director To Expand Kidney Disease Services 2Health News:Lierac Paris Expands in the United States at Healthy Skincare Centers at CVS/pharmacy 2Health News:Lierac Paris Expands in the United States at Healthy Skincare Centers at CVS/pharmacy 3Health News:Microwave treatments for enlarged prostate cause blood pressure surges 2Health News:Use of information technology is minimal in nursing homes 2Health News:Metrologic and Wake Forest University Baptist Medical Center Sponsored Healthcare Educational Forum 2Health News:Metrologic and Wake Forest University Baptist Medical Center Sponsored Healthcare Educational Forum 3Health News:GlaxoSmithKline Confirms Receipt of FDA Letter on Regulatory Reporting 2
(Date:6/1/2015)... -- LaunchPad Medical, LLC announced today that it has ... Corporation,s (NYSE: SYK ) bone adhesive technology, ... Under the terms of the agreement, LaunchPad has ... this technology which is covered by four issued ... from multiple pre-clinical animal studies.  LaunchPad will seek ...
(Date:6/1/2015)... -- Lee Tran & Liang LLP (LTL), ... and Yik Yak co-founder disputes, announced today ... most promising biotechnology start-ups in the country, Resilience Therapeutics, ... Sabados .  LTL represents Veronica Sara Weiner , ... fellow scientist at the Massachusetts Institute of Technology.      ...
(Date:6/1/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) ... focus on Omega-3 therapies for cardiovascular disease (CVD) ... financial results for the three months ended March ... in Canadian dollars unless otherwise stated. ... despite its limited financial resources," stated Mr. ...
Breaking Medicine Technology:LaunchPad Medical Executes Definitive License Agreement with Stryker for Novel Bone Adhesive Technology 2Lee Tran & Liang LLP Files Co-Founder Lawsuit against Leading Biotech Start-up Resilience 2Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5
... EASTON, Mass., March 19 Pressure,BioSciences, Inc. (Nasdaq: ... the Company and the Harvard School of Public ... simultaneous extraction, isolation, and,fractionation of nucleic acids (DNA ... samples routinely used in laboratory research. The method,is ...
... Meeting Indicates New Catheter-based, Treatment Could Soon ... DVT, WASHINGTON, March 19 Registry clinical ... Radiology,s 33rd Annual,Scientific Meeting shows DVT treatment with ... (Santa Clara, CA) successfully,breaks up the blood clot ...
Cached Medicine Technology:Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health 2Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health 3Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health 4Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients 2
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
... ,Launched in 1988, this design revolutionized ... standard practice in general anesthesia. Used successfully ... Classic™ is a safe hands free alternative ... Classic™ can be used for a wide ...
Medicine Products: